The OPTION trial evaluated IV tenecteplase (0.25 mg/kg) in CT perfusion–selected non-LVO ischemic stroke patients treated 4.5–24 hours after last-known-well. Tenecteplase improved excellent 90-day outcomes (mRS 0–1) but increased symptomatic intracranial hemorrhage, with the benefit–harm balance sensitive to outcome and ...
The EVERDAC trial sought to determine if managing shock with noninvasive brachial cuff monitoring is noninferior to early (<4 hours) arterial catheter placement
Mindset shapes everything we do in medicine—from how we teach and learn to how we show up for patients at the bedside. In this episode, we delve into how the mindset of clinicians can profoundly influence their performance, professional growth, ...
The HAT and SEDAN scores help estimate symptomatic intracranial hemorrhage risk after stroke thrombolysis. This comparison reviews what each tool measures, when to use them, and the key limitations clinicians should know.
STEMI-equivalent and STEMI-mimic ECGs are among the most difficult tracings to interpret. This study examines how Queen of Hearts AI performed against physicians when accuracy in cath lab activation decisions mattered most.
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
